A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LPM6690176 Capsules in Patients With Advanced Solid Tumors.
This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.
评价LPM6690176胶囊在晚期恶性实体瘤患者中的安全耐受性、药代动力学特征和初步疗效的非随机、开放、I期临床研究
评价LPM6690176胶囊在晚期恶性实体瘤患者中的安全耐受性,观察剂量限制性毒性(DLT),确定最大耐受剂量(MTD);评价LPM6690176胶囊在晚期恶性实体瘤患者中的药代动力学(PK)特征和初步疗效;
100 项与 LPM6690176 相关的临床结果
100 项与 LPM6690176 相关的转化医学
100 项与 LPM6690176 相关的专利(医药)
100 项与 LPM6690176 相关的药物交易